

Friedemann Paul

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5448003/publications.pdf](https://exaly.com/author-pdf/5448003/publications.pdf)

Version: 2024-02-01

565
papers

30,303
citations

5727

83
h-index

9570

144
g-index

607
all docs

607
docs citations

607
times ranked

30259
citing authors

#	ARTICLE	IF	CITATIONS
1	Interactions of optic radiation lesions with retinal and brain atrophy in early multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2024, 11, 45-56.	3.7	0
2	Time to Disability Milestones and Annualized Relapse Rates in <scp>NMOSD</scp> and <scp>MOGAD</scp>. <i>Annals of Neurology</i> , 2024, 95, 720-732.	5.8	5
3	Effect of amniotic membrane/collagen scaffolds on laryngeal cartilage repair. <i>Laryngoscope Investigative Otolaryngology</i> , 2024, 9, .	1.4	0
4	Clinical Characterization and Ancillary Tests in Susac Syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2024, 11, .	6.8	2
5	An exploratory research report on brain mineralization in postoperative delirium and cognitive decline. <i>European Journal of Neuroscience</i> , 2024, 59, 2646-2664.	3.5	1
6	Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories. <i>Science Translational Medicine</i> , 2024, 16, .	13.4	4
7	Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis. <i>Annals of Neurology</i> , 2024, 96, 276-288.	5.8	0
8	Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2024, 11, .	6.8	0
9	Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness <i>z</i> Scores. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2024, 11, .	6.8	0
10	Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2024, 11, .	6.8	0
11	Diagnostic Value of Inter-Eye Difference Metrics on OCT for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2024, 11, .	6.8	0
12	Eculizumab Use in Neuromyelitis Optica Spectrum Disorders. <i>Neurology</i> , 2024, 103, .	1.1	0
13	Inelastic x-ray scattering (IXS) spectrometer design studies at LCLS. , 2024, , 19.		0
14	Multiple sclerosis and circadian rhythms: Can diet act as a treatment?. <i>Acta Physiologica</i> , 2023, 237, .	3.9	7
15	Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. <i>Annals of Neurology</i> , 2023, 93, 1053-1068.	5.8	43
16	Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of <scp><i>FCGR3A</i></scp> polymorphism. <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 2413-2420.	3.7	3
17	Confined-microtubule assembly shapes three-dimensional cell wall structures in xylem vessels. <i>Nature Communications</i> , 2023, 14, .	13.2	7
18	Transparent Waterborne Polyurethane Composite Reinforced with Chitosan Nanofibers. <i>Journal of Chitin and Chitosan</i> , 2023, 28, 183-188.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Decreased Serum Neurofilament Light Chain and Fatigue Severity in Patients with Multiple Sclerosis after Home-Based and Outdoor Pilates Training. , 2023, 17, 55-62.		0
20	Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2022, 28, 757-767.	3.3	3
21	Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry. Multiple Sclerosis Journal, 2022, 28, 865-871.	3.3	8
22	Modular deep neural networks for automatic quality control of retinal optical coherence tomography scans. Computers in Biology and Medicine, 2022, 141, 104822.	7.3	13
23	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 188-195.	6.0	15
24	In vivo stiffness of multiple sclerosis lesions is similar to that of normal-appearing white matter. Acta Biomaterialia, 2022, 138, 410-421.	8.8	12
25	Frailty and Falls in People Living With Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation, 2022, 103, 952-957.	1.0	9
26	Immune signature of multiple sclerosis-associated depression. Brain, Behavior, and Immunity, 2022, 100, 174-182.	6.3	8
27	OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103525.	2.1	44
28	Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina. Multiple Sclerosis and Related Disorders, 2022, 58, 103466.	2.1	3
29	Proposal for Post Hoc Quality Control in Instrumented Motion Analysis Using Markerless Motion Capture: Development and Usability Study. JMIR Human Factors, 2022, 9, e26825.	2.0	3
30	Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry. Neurology and Therapy, 2022, 11, 319-336.	3.5	3
31	State-dependent signatures of anti-N-methyl-D-aspartate receptor encephalitis. Brain Communications, 2022, 4, fcab298.	3.4	14
32	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. Annals of Neurology, 2022, 91, 192-202.	5.8	20
33	On the origin of magnetic fields in stars II. The effect of numerical resolution. Monthly Notices of the Royal Astronomical Society, 2022, 511, 746-764.	4.6	10
34	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. Neurology, 2022, 98, .	1.1	14
35	Teriflunomide Preserves Neuronal Activity and Protects Mitochondria in Brain Slices Exposed to Oxidative Stress. International Journal of Molecular Sciences, 2022, 23, 1538.	4.2	10
36	Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly. Journal of Immunology, 2022, 208, 1001-1005.	0.8	19

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.8	42
38	Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.8	42
39	Prospective Study Assessing Impact of Ethylene Oxide Sterilization on Endoscopic Ultrasound Image Quality. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2780-2789.	4.7	2
40	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgGâ€“Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.8	79
41	Anatomical and functional visual network patterns in progressive multiple sclerosis. <i>Human Brain Mapping</i> , 2022, 43, 1590-1597.	3.7	3
42	Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.8	40
43	Diagnostic efficacy of the magnetic resonance T1w/T2w ratio for the middle cerebellar peduncle in multiple system atrophy and spinocerebellar ataxia: A preliminary study. <i>PLoS ONE</i> , 2022, 17, e0267024.	2.5	1
44	CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage. <i>Journal of Neuroinflammation</i> , 2022, 19, 86.	7.4	15
45	Different Impact of Gadopentetate and Gadobutrol on Inflammation-Promoted Retention and Toxicity of Gadolinium Within the Mouse Brain. <i>Investigative Radiology</i> , 2022, 57, 677-688.	6.3	8
46	Intraretinal Layer Segmentation Using Cascaded Compressed U-Nets. <i>Journal of Imaging</i> , 2022, 8, 139.	3.1	10
47	Preventing Axonal Sodium Overload or Mitochondrial Calcium Uptake Protects Axonal Mitochondria from Oxidative Stress-Induced Alterations. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-13.	4.1	3
48	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1859-1870.	3.3	18
49	Prefrontal-amygdala emotion regulation and depression in multiple sclerosis. <i>Brain Communications</i> , 2022, 4, .	3.4	7
50	Longitudinal Retinal Changes in <sc>MOGAD</sc>. <i>Annals of Neurology</i> , 2022, 92, 476-485.	5.8	24
51	Prediction of high and low disease activity in early MS patients using multiple kernel learning identifies importance of lateral ventricle intensity. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211097.	1.1	3
52	SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 960-971.	6.0	22
53	Prior optic neuritis detection on peripapillary ring scans using deep learning. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1682-1691.	3.7	4
54	Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. <i>Blood</i> , 2022, 140, 10357-10359.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Functional connectivity alterations of striato-cortical circuits in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1469-1470.	3.3	1
56	Magnetic resonance T1w/T2w ratio in the middle cerebellar peduncle might be a sensitive biomarker for multiple system atrophy. <i>European Radiology</i> , 2021, 31, 4277-4284.	4.6	8
57	Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 377-383.	6.0	19
58	The Worm-Specific Immune Response in Multiple Sclerosis Patients Receiving Controlled <i>Trichuris suis</i> Ova Immunotherapy. <i>Life</i> , 2021, 11, 101.	2.5	11
59	A novel investigation method for axonal damage in neuromyelitis optica spectrum disorder: In vivo corneal confocal microscopy. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732199806.	1.1	1
60	Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	3
61	Pain, depression, and quality of life in adults with MOG-antibody-associated disease. <i>European Journal of Neurology</i> , 2021, 28, 1645-1658.	3.6	15
62	Sensitivity analysis of the primary endpoint from the N-MOMentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	3.3	13
63	544 Neonatal intensive care admission is associated with lower breastfeeding in late preterm infants. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, S344-S345.	1.3	0
64	Epigallocatechin Gallate in Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.8	13
65	Toward understanding the underlying mechanisms of pelvic tilt reserve in adult spinal deformity: the role of the 3D hip orientation. <i>European Spine Journal</i> , 2021, 30, 2495-2503.	2.3	8
66	Practical recognition tools of immunoglobulin G serum antibodies against the myelin oligodendrocyte glycoprotein-positive optic neuritis and its clinical implications. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 42-53.	0.9	4
67	Cultural bias in motor function patterns: Potential relevance for predictive, preventive, and personalized medicine. <i>EPMA Journal</i> , 2021, 12, 91-101.	6.1	4
68	Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.8	17
69	Foveal changes in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive. <i>European Journal of Neurology</i> , 2021, 28, 2280-2293.	3.6	14
70	Differenzialdiagnostik autoimmun-entzündlicher Rückenmarkserkrankungen. <i>Der Nervenarzt</i> , 2021, 92, 293-306.	0.8	2
71	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.8	28
72	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021, 89, 895-910.	5.8	87

#	ARTICLE	IF	CITATIONS
73	Accelerating clinical research in neuromyelitis optica spectrum disorders. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 89-91.	0.9	3
74	Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2180-2190.	3.3	12
75	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021, 97, 68-79.	1.1	122
76	Retinal Thickness Analysis in Progressive Multiple Sclerosis Patients Treated With Epigallocatechin Gallate: Optical Coherence Tomography Results From the SUPREMES Study. <i>Frontiers in Neurology</i> , 2021, 12, 615790.	2.5	9
77	Effect of Nabiximols On Goal Attainment Scale Scores in Patients With treatment-resistant Multiple Sclerosis Spasticity. <i>Neurodegenerative Disease Management</i> , 2021, 11, 143-153.	2.3	3
78	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.8	48
79	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110068.	1.1	6
80	Artificial intelligence extension of the OSCAR criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1528-1542.	3.7	34
81	Simultaneous T2 and mapping of multiple sclerosis lesions with radial RARE-EPI. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 1383-1402.	3.1	3
82	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. <i>Journal of Neuroinflammation</i> , 2021, 18, 105.	7.4	50
83	Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry. <i>Scientific Reports</i> , 2021, 11, 13340.	3.4	33
84	Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration. <i>JAMA Neurology</i> , 2021, 78, 842.	9.3	19
85	Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells. <i>Neurotherapeutics</i> , 2021, 18, 1783-1797.	4.7	7
86	Clinical and neuroimaging findings in MOGAD-MRI and OCT. <i>Clinical and Experimental Immunology</i> , 2021, 206, 266-281.	2.7	30
87	Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.8	74
88	Cross-reactive CD4 ⁺ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. <i>Science</i> , 2021, 374, eabh1823.	20.9	241
89	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103080.	2.1	7
90	Perception and practice of early initiation of breastfeeding and associated factors among postnatal mothers in East Sikkim. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , 2021, 10, 3494.	0.1	0

#	ARTICLE	IF	CITATIONS
91	Increased Serum Neurofilament Light and Thin Ganglion Cellâ€™Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.8	32
92	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.8	52
93	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology, The</i> , 2021, 20, 762-772.	10.4	305
94	Identification of the gliogenic state of human neural stem cells to optimize in vitro astrocyte differentiation. <i>Journal of Neuroscience Methods</i> , 2021, 361, 109284.	2.6	7
95	Retinal optical coherence tomography and magnetic resonance imaging in neuromyelitis optica spectrum disorders and MOG-antibody associated disorders: an updated review. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1101-1123.	2.8	9
96	Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany â€™ A registry-based/multicentric cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103281.	2.1	7
97	C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. <i>Journal of Neuroimmunology</i> , 2021, 360, 577699.	2.4	18
98	<i>In vivo</i> detection of teriflunomide-derived fluorine signal during neuroinflammation using fluorine MR spectroscopy. <i>Theranostics</i> , 2021, 11, 2490-2504.	9.9	10
99	A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110143.	3.8	17
100	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study. <i>NeuroImage: Clinical</i> , 2021, 30, 102608.	2.8	9
101	<i>N2</i> year in review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.8	3
102	Optical coherence tomography in multiple sclerosis: A 3â€™year prospective multicenter study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2235-2251.	3.7	45
103	Neural Processes of Psychological Stress and Relaxation Predict the Future Evolution of Quality of Life in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 753107.	2.5	8
104	Pharmakologische Behandlung der multiplen Sklerose. , 2021, , 561-578.		0
105	Visualising Multiplayer Game Spaces. <i>IEEE Transactions on Games</i> , 2021, , 1-1.	1.6	1
106	Patch individual filter layers in CNNs to harness the spatial homogeneity of neuroimaging data. <i>Scientific Reports</i> , 2021, 11, 24447.	3.4	5
107	Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders. <i>Acta Neurologica Belgica</i> , 2020, 120, 223-225.	1.1	12
108	Brain Iron and Metabolic Abnormalities in C19orf12 Mutation Carriers: A 7.0 Tesla MRI Study in Mitochondrial Membrane Proteinâ€™Associated Neurodegeneration. <i>Movement Disorders</i> , 2020, 35, 142-150.	4.3	16

#	ARTICLE	IF	CITATIONS
109	Ketogenic diet and fasting diet as Nutritional Approaches in Multiple Sclerosis (NAMS): protocol of a randomized controlled study. <i>Trials</i> , 2020, 21, 3.	1.7	60
110	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020, 11, 579438.	2.5	10
111	Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102485.	2.1	28
112	Instrumental Assessment of Stepping in Place Captures Clinically Relevant Motor Symptoms of Parkinson's Disease. <i>Sensors</i> , 2020, 20, 5465.	4.0	10
113	N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation. <i>Journal of Biological Chemistry</i> , 2020, 295, 17413-17424.	3.5	31
114	Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis. <i>Neurobiology of Stress</i> , 2020, 13, 100244.	4.1	10
115	Genetic determinants of the humoral immune response in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.8	7
116	Visual system damage and network maladaptation are associated with cognitive performance in neuromyelitis optica spectrum disorders.. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102406.	2.1	12
117	Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis. <i>Scientific Reports</i> , 2020, 10, 8776.	3.4	4
118	Functionally Relevant Maculopathy and Optic Atrophy in Spinocerebellar Ataxia Type 1. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 502-508.	1.7	8
119	Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. <i>Brain</i> , 2020, 143, 3574-3588.	8.0	130
120	Aggressive multiple sclerosis: a matter of measurement and timing. <i>Brain</i> , 2020, 143, e97-e97.	8.0	9
121	Conduction delays in the visual pathways of progressive multiple sclerosis patients covary with brain structure. <i>NeuroImage</i> , 2020, 221, 117204.	4.4	17
122	Emerging drugs for the treatment of neuromyelitis optica. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 285-297.	2.4	14
123	Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102579.	2.1	15
124	Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study. <i>Frontiers in Neurology</i> , 2020, 11, 499910.	2.5	15
125	Altered Coupling of Psychological Relaxation and Regional Volume of Brain Reward Areas in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 568850.	2.5	3
126	Teriflunomide preserves peripheral nerve mitochondria from oxidative stress-mediated alterations. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232094477.	2.6	9

#	ARTICLE	IF	CITATIONS
127	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 261.	7.4	92
128	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 262.	7.4	47
129	Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1628-1641.	3.7	4
130	Sex differences in brain atrophy in multiple sclerosis. <i>Biology of Sex Differences</i> , 2020, 11, 49.	4.2	57
131	Quantitative Multi-Parameter Mapping Optimized for the Clinical Routine. <i>Frontiers in Neuroscience</i> , 2020, 14, 611194.	2.9	20
132	The comparison of different acupuncture therapies for post stroke depression. <i>Medicine (United Kingdom)</i> , 2020, 99, 111111.	1.1	1
133	Pain in NMO and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. <i>Frontiers in Neurology</i> , 2020, 11, 778.	2.5	43
134	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	2.1	11
135	Simple Flow-Based System with an In-Line Membrane Gas-Liquid Separation Unit and a Contactless Conductivity Detector for the Direct Determination of Sulfite in Clear and Turbid Food Samples. <i>Membranes</i> , 2020, 10, 104.	3.0	5
136	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 681-686.	6.0	71
137	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020, 56, 102807.	6.0	82
138	Is APOE ϵ 4 associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.8	12
139	Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. <i>Nature Communications</i> , 2020, 11, 2856.	13.2	58
140	Identifying Progression in Multiple Sclerosis: New Perspectives. <i>Annals of Neurology</i> , 2020, 88, 438-452.	5.8	75
141	Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 450.	2.5	31
142	Impact of treatment on cellular immunophenotype in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.8	20
143	Wisdom of the expert crowd prediction of response for 3 neurology randomized trials. <i>Neurology</i> , 2020, 95, e488-e498.	1.1	5
144	A new FRET probe for ratiometric fluorescence detecting mitochondria-localized drug activation and imaging endogenous hydroxyl radicals in zebrafish. <i>Chemical Communications</i> , 2020, 56, 4432-4435.	4.2	42

#	ARTICLE	IF	CITATIONS
145	Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1061-1072.	3.2	15
146	Vitamin D and Disease Severity in Multiple Sclerosis—Baseline Data From the Randomized Controlled Trial (EVIDIMS). <i>Frontiers in Neurology</i> , 2020, 11, 129.	2.5	16
147	Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) — preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial. <i>BMC Neurology</i> , 2020, 20, 75.	1.8	11
148	Investigation of Visual System Involvement in Spinocerebellar Ataxia Type 14. <i>Cerebellum</i> , 2020, 19, 469-482.	2.7	3
149	Altered fovea in AQP4-IgG—seropositive neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.8	51
150	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. <i>Frontiers in Neurology</i> , 2020, 11, 501.	2.5	242
151	DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning. <i>PLoS Computational Biology</i> , 2020, 16, e1007616.	3.1	60
152	Highly Stretchable Polymer Composite with Strain—Enhanced Electromagnetic Interference Shielding Effectiveness. <i>Advanced Materials</i> , 2020, 32, e1907499.	24.3	273
153	Binding patterns and functional properties of human antibodies to AQP4 and MOG on murine optic nerve and retina. <i>Journal of Neuroimmunology</i> , 2020, 342, 577194.	2.4	3
154	Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102027.	2.1	12
155	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 94, e407-e418.	1.1	38
156	Prodromal headache in MOG-antibody positive optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101965.	2.1	43
157	Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. <i>Acta Neuropathologica</i> , 2020, 139, 547-564.	7.9	12
158	Association Between Fatigue and Motor Exertion in Patients With Multiple Sclerosis—a Prospective Study. <i>Frontiers in Neurology</i> , 2020, 11, 208.	2.5	21
159	Longitudinal ultra-high field MRI of brain lesions in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102066.	2.1	4
160	Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders. <i>European Radiology</i> , 2020, 30, 5048-5058.	4.6	11
161	<i>N2</i> year in review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.8	1
162	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. <i>Brain</i> , 2020, 143, 1127-1142.	8.0	30

#	ARTICLE	IF	CITATIONS
163	Evaluation of the "ring sign"™ and the "core sign"™ as a magnetic resonance imaging marker of disease activity and progression in clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732091548.	1.1	25
164	Cortical topological network changes following optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.8	10
165	Considerations for Mean Upper Cervical Cord Area Implementation in a Longitudinal MRI Setting: Methods, Interrater Reliability, and MRI Quality Control. American Journal of Neuroradiology, 2020, 41, 343-350.	2.7	8
166	Transdiagnostic hippocampal damage patterns in neuroimmunological disorders. NeuroImage: Clinical, 2020, 28, 102515.	2.8	11
167	Transient enlargement of brain ventricles during relapsing-remitting multiple sclerosis and experimental autoimmune encephalomyelitis. JCI Insight, 2020, 5, .	5.0	15
168	High-dose vitamin D supplementation in multiple sclerosis " results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732090347.	1.1	27
169	An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis. International Journal of MS Care, 2020, 22, 226-232.	1.0	17
170	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurology, 2019, 76, 1446.	9.3	136
171	Diagnostik und Therapie von Tuberkulose unter Immuntherapien ¼r Multiple Sklerose. Der Nervenarzt, 2019, 90, 1245-1253.	0.8	3
172	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2019, 18, 724-735.	10.4	85
173	Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study. Brain Communications, 2019, 1, fcz026.	3.4	16
174	EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases. PLoS ONE, 2019, 14, e0223886.	2.5	11
175	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, The, 2019, 394, 1352-1363.	12.1	477
176	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731987158.	1.1	38
177	Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis. Neurology, 2019, 93, e1439-e1451.	1.1	43
178	Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation. NeuroImage: Clinical, 2019, 24, 102003.	2.8	100
179	Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e572.	6.8	147
180	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain, 2019, 142, 1858-1875.	8.0	346

#	ARTICLE	IF	CITATIONS
181	Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy. <i>BMC Neurology</i> , 2019, 19, 118.	1.8	1
182	Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features. <i>Frontiers in Neurology</i> , 2019, 10, 608.	2.5	48
183	Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1156-1164.	6.0	20
184	Olfactory and Gustatory Dysfunction in Patients With Autoimmune Encephalitis. <i>Frontiers in Neurology</i> , 2019, 10, 480.	2.5	7
185	Neural mechanisms of perceptual decision-making and their link to neuropsychiatric symptoms in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 139-145.	2.1	4
186	Vision and Vision-Related Measures in Progressive Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 455.	2.5	17
187	MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9671-9676.	7.6	45
188	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 841.	9.3	55
189	Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 334.	2.5	33
190	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. <i>Annals of Neurology</i> , 2019, 85, 618-629.	5.8	112
191	N2 year in review and message from the editor to our reviewers. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e525.	6.8	1
192	Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e541.	6.8	16
193	Search for heavy resonances decaying into two Higgs bosons or into a Higgs boson and a W or Z boson in proton-proton collisions at 13 TeV. <i>Journal of High Energy Physics</i> , 2019, 2019, 1.	4.8	12
194	THE AGING JOURNEY RAILWAY, ILLICIT DRUG (DE)RAILS, AND CARE: OLDER USERS IN BRAZIL AND PORTUGAL. <i>Innovation in Aging</i> , 2019, 3, S310-S311.	0.1	0
195	Contactless recording of sleep apnea and periodic leg movements by nocturnal 3-D-video and subsequent visual perceptive computing. <i>Scientific Reports</i> , 2019, 9, 16812.	3.4	15
196	Multi-parameter immune profiling of peripheral blood mononuclear cells by multiplexed single-cell mass cytometry in patients with early multiple sclerosis. <i>Scientific Reports</i> , 2019, 9, 19471.	3.4	40
197	Low-Density Granulocytes Are a Novel Immunopathological Feature in Both Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2019, 10, 2725.	4.9	25
198	Suggestions for improving the design of clinical trials in multiple sclerosis—results of a systematic analysis of completed phase III trials. <i>EPMA Journal</i> , 2019, 10, 425-436.	6.1	34

#	ARTICLE	IF	CITATIONS
199	Increased Retention of Gadolinium in the Inflamed Brain After Repeated Administration of Gadopentetate Dimeglumine. <i>Investigative Radiology</i> , 2019, 54, 617-626.	6.3	32
200	Normative Data and Minimally Detectable Change for Inner Retinal Layer Thicknesses Using a Semi-automated OCT Image Segmentation Pipeline. <i>Frontiers in Neurology</i> , 2019, 10, 1117.	2.5	38
201	Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 64-68.	2.1	50
202	Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 31-43.	2.8	46
203	Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1926-1936.	3.3	51
204	Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation. <i>Nature Communications</i> , 2019, 10, 217.	13.2	60
205	Sex differences in autoimmune disorders of the central nervous system. <i>Seminars in Immunopathology</i> , 2019, 41, 177-188.	6.4	81
206	Gadolinium in human brain sections and colocalization with other elements. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e515.	6.8	22
207	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). <i>Journal of Neurology</i> , 2019, 266, 386-397.	3.8	28
208	Association of smoking but not HLA-DRB1*15:01, <i>APOE</i> or body mass index with brain atrophy in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 661-668.	3.3	14
209	Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex. <i>Multiple Sclerosis Journal</i> , 2019, 25, 554-564.	3.3	77
210	Flammer Syndrome and Autoimmune Inflammatory Conditions of the Central Nervous System: Multifactorial Interrelations. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2019, , 145-163.	0.0	1
211	Multiple Sclerosis. <i>Contemporary Clinical Neuroscience</i> , 2019, , 487-521.	0.0	2
212	Automatic quality evaluation as assessment standard for optical coherence tomography. , 2019, , .		2
213	Investigational drugs in development to prevent neuromyelitis optica relapses. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 265-271.	4.0	41
214	Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. <i>EPMA Journal</i> , 2018, 9, 21-33.	6.1	76
215	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. <i>Nature Reviews Neurology</i> , 2018, 14, 199-213.	10.0	165
216	Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome. <i>JAMA Neurology</i> , 2018, 75, 1071.	9.3	77

#	ARTICLE	IF	CITATIONS
217	The effectiveness of acupuncture and mindfulness-based stress reduction (MBSR) for patients with multiple sclerosis associated fatigue – A study protocol and its rationale for a randomized controlled trial. <i>European Journal of Integrative Medicine</i> , 2018, 20, 6-15.	1.8	2
218	Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon. <i>Journal of the Neurological Sciences</i> , 2018, 387, 60-69.	0.6	5
219	Worldwide prevalence of neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 555-556.	6.0	90
220	<i>SIX1</i> and <i>DACH1</i> influence the proliferation and apoptosis of hepatocellular carcinoma through regulating p53. <i>Cancer Biology and Therapy</i> , 2018, 19, 381-390.	3.7	30
221	Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis. <i>JAMA Neurology</i> , 2018, 75, 287.	9.3	41
222	Pursuing functional connectivity in NMDAR1 autoantibody carriers – Authors' reply. <i>Lancet Psychiatry</i> , 2018, 5, 22.	7.6	1
223	Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e423.	6.8	57
224	Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization. <i>JAMA Neurology</i> , 2018, 75, 296.	9.3	38
225	Magnetic resonance imaging findings at the first episode of acute optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 30-36.	2.1	23
226	Frequent retinal ganglion cell damage after acute optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 141-147.	2.1	30
227	Multicenter reliability of semiautomatic retinal layer segmentation using OCT. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e449.	6.8	79
228	Treatment choices and neuropsychological symptoms of a large cohort of early MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e446.	6.8	56
229	Brain activity, regional gray matter loss, and decision-making in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1163-1173.	3.3	21
230	Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1737-1742.	3.3	42
231	Superficial white matter damage in anti-NMDA receptor encephalitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 518-525.	6.0	61
232	A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 330-338.	6.0	23
233	Self-perception and determinants of color vision in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 145-152.	2.9	9
234	Leptomeningeal and Intraparenchymal Blood Barrier Disruption in a MOG-IgG-Positive Patient. <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-3.	0.4	7

#	ARTICLE	IF	CITATIONS
235	The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis. <i>Journal of Neuro-Ophthalmology</i> , 2018, 38, 494-501.	0.8	17
236	Ozanimod for the treatment of relapsing remitting multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2073-2086.	1.9	35
237	Optische Kohärenztomografie bei Erkrankungen des zentralen Nervensystems. <i>Klinische Monatsblätter Für Augenheilkunde</i> , 2018, 235, 1242-1258.	0.4	6
238	Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. <i>Frontiers in Neurology</i> , 2018, 9, 888.	2.5	199
239	Metabolic, Mental and Immunological Effects of Normoxic and Hypoxic Training in Multiple Sclerosis Patients: A Pilot Study. <i>Frontiers in Immunology</i> , 2018, 9, 2819.	4.9	23
240	Pro-inflammatory Monocyte Phenotype and Cell-Specific Steroid Signaling Alterations in Unmedicated Patients With Major Depressive Disorder. <i>Frontiers in Immunology</i> , 2018, 9, 2693.	4.9	42
241	Microscopic origin of Cooper pairing in the iron-based superconductor Ba _{1-x} K _x Fe ₂ As ₂ . <i>Npj Quantum Materials</i> , 2018, 3, .	5.2	17
242	Venoplasty in MS. <i>Neurology</i> , 2018, 91, 815-816.	1.1	0
243	Objective assessment of a relative afferent pupillary defect by B-mode ultrasound. <i>PLoS ONE</i> , 2018, 13, e0202774.	2.5	5
244	Racial differences in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2018, 91, e2089-e2099.	1.1	148
245	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	6.8	187
246	MRI Markers and Functional Performance in Patients With CIS and MS: A Cross-Sectional Study. <i>Frontiers in Neurology</i> , 2018, 9, 718.	2.5	15
247	Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging. <i>PLoS ONE</i> , 2018, 13, e0202918.	2.5	37
248	Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731879668.	1.1	45
249	Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. <i>EPMA Journal</i> , 2018, 9, 249-256.	6.1	33
250	Temporal visual resolution and disease severity in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e492.	6.8	15
251	Comparison of probabilistic tractography and tract-based spatial statistics for assessing optic radiation damage in patients with autoimmune inflammatory disorders of the central nervous system. <i>NeuroImage: Clinical</i> , 2018, 19, 538-550.	2.8	40
252	Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1259-1265.	6.0	105

#	ARTICLE	IF	CITATIONS
253	MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 66-72.	2.1	160
254	Omics-Based Approach Reveals Complement-Mediated Inflammation in Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). <i>Frontiers in Immunology</i> , 2018, 9, 741.	4.9	10
255	VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e475.	6.8	15
256	MRI-Based Methods for Spinal Cord Atrophy Evaluation: A Comparison of Cervical Cord Cross-Sectional Area, Cervical Cord Volume, and Full Spinal Cord Volume in Patients with Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders. <i>American Journal of Neuroradiology</i> , 2018, 39, 1362-1368.	2.7	13
257	Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 78-82.	2.1	39
258	Optical coherence tomography in acute optic neuritis: A population-based study. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 566-573.	2.2	44
259	7 Tesla MRI of Balo's concentric sclerosis versus multiple sclerosis lesions. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 900-912.	3.7	14
260	Beyond the limbic system: disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1191-1199.	6.0	51
261	Less Is More – Estimation of the Number of Strides Required to Assess Gait Variability in Spatially Confined Settings. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 435.	3.5	46
262	Optic nerve head three-dimensional shape analysis. <i>Journal of Biomedical Optics</i> , 2018, 23, 1.	2.8	9
263	Active contour method for ILM segmentation in ONH volume scans in retinal OCT. <i>Biomedical Optics Express</i> , 2018, 9, 6497.	3.0	11
264	Implementação de um algoritmo rápido para alta hospitalar precoce após ressecção de tumor cerebral. <i>Brazilian Neurosurgery</i> , 2018, 37, .	0.1	0
265	Subjective and objective assessment of physical activity in multiple sclerosis and their relation to health-related quality of life. <i>BMC Neurology</i> , 2017, 17, 10.	1.8	18
266	Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 11, 45-50.	2.1	92
267	Inflammation-induced brain endothelial activation leads to uptake of electrostatically stabilized iron oxide nanoparticles via sulfated glycosaminoglycans. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1411-1421.	3.5	20
268	The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice. <i>BMC Neuroscience</i> , 2017, 18, 19.	1.8	46
269	Alzheimer's disease: Elevated pigment epithelium-derived factor in the cerebrospinal fluid is mostly of systemic origin. <i>Journal of the Neurological Sciences</i> , 2017, 375, 123-128.	0.6	8
270	Microstructural visual system changes in AQP4-antibody seropositive NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e334.	6.8	130

#	ARTICLE	IF	CITATIONS
271	Tensor Algebras. , 2017, , 21-56.		0
272	Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Scientific Reports, 2017, 7, 43718.	3.4	35
273	Singleâ€subject independent component analysisâ€based intensity normalization in nonâ€quantitative multiâ€modal structural MRI. Human Brain Mapping, 2017, 38, 3615-3622.	3.7	1
274	Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e338.	6.8	19
275	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e343.	6.8	57
276	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 639-647.	6.0	128
277	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e339.	6.8	33
278	Untersuchungen des visuellen Systems in der Neurologie: aktuelle Forschung und klinische Relevanz. Aktuelle Neurologie, 2017, 44, 27-45.	0.3	4
279	Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies. JAMA Neurology, 2017, 74, 50.	9.3	232
280	What should a person with relapsing-remitting multiple sclerosis know? â€ Focus group and survey data of a risk knowledge questionnaire (RIKNO 2.0). Multiple Sclerosis and Related Disorders, 2017, 18, 186-195.	2.1	10
281	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology, 2017, 89, 2238-2244.	1.1	62
282	Fatigue as a symptom or comorbidity of neurological diseases. Nature Reviews Neurology, 2017, 13, 662-675.	10.0	286
283	Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. Multiple Sclerosis and Related Disorders, 2017, 17, 198-201.	2.1	38
284	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurology, The, 2017, 16, 797-812.	10.4	434
285	Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis: an observational study. Lancet Psychiatry,the, 2017, 4, 768-774.	7.6	117
286	Synapsin-antibodies in psychiatric and neurological disorders: Prevalence and clinical findings. Brain, Behavior, and Immunity, 2017, 66, 125-134.	6.3	16
287	Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis. Scientific Reports, 2017, 7, 5995.	3.4	25
288	Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. Journal of Neurology, 2017, 264, 1370-1380.	3.8	58

#	ARTICLE	IF	CITATIONS
289	Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system. EPMA Journal, 2017, 8, 279-294.	6.1	36
290	Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. EPMA Journal, 2017, 8, 313-325.	6.1	99
291	Optische Kohärenztomographie bei Neuromyelitis optica-Spektrum-Erkrankungen. Der Nervenarzt, 2017, 88, 1411-1420.	0.8	4
292	Olfactory dysfunction in patients with primary progressive MS. Neurology: Neuroimmunology and Neuroinflammation, 2017, 4, e369.	6.8	13
293	Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density. Multiple Sclerosis Journal, 2017, 23, 1847-1853.	3.3	68
294	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2017, 23, 1092-1103.	3.3	62
295	Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder. European Radiology, 2017, 27, 2206-2215.	4.6	18
296	Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients. Multiple Sclerosis Journal, 2017, 23, 963-972.	3.3	66
297	Optische Kohärenztomografie in der Neurologie – Methodik und Anwendung in Forschung und Klinik. Klinische Neurophysiologie, 2017, 48, 211-225.	0.1	2
298	CuBe: parametric modeling of 3D foveal shape using cubic Bézier. Biomedical Optics Express, 2017, 8, 4181.	3.0	17
299	Dynamics and heterogeneity of brain damage in multiple sclerosis. PLoS Computational Biology, 2017, 13, e1005757.	3.1	37
300	Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. Journal of Neuroinflammation, 2017, 14, 172.	7.4	17
301	The chronically inflamed central nervous system provides niches for long-lived plasma cells. Acta Neuropathologica Communications, 2017, 5, 88.	5.4	56
302	Streptococcus pneumoniae and lytic antibiotic therapy: are we adding insult to injury during invasive pneumococcal disease and sepsis?. Journal of Medical Microbiology, 2017, 66, 1253-1256.	1.8	11
303	Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. PLoS ONE, 2017, 12, e0175279.	2.5	32
304	B-mode ultrasound assessment of pupillary function: Feasibility, reliability and normal values. PLoS ONE, 2017, 12, e0189016.	2.5	15
305	Maximum walking speed in multiple sclerosis assessed with visual perceptive computing. PLoS ONE, 2017, 12, e0189281.	2.5	30
306	Late Breaking Abstract - Adherence to GOLD recommendations in Italian COPD patients stratified by GOLD groups – D: The MISTRAL study. European Respiratory Journal, 2017, , .	7.5	0

#	ARTICLE	IF	CITATIONS
307	Pengaruh Locus Of Control Dan Turnover Intention Terhadap Perilaku Disfungsional Serta Dampaknya Terhadap Kualitas Audit. STAR, 2017, 14, 13.	0.0	0
308	Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod. Case Reports in Neurological Medicine, 2016, 2016, 1-8.	0.4	13
309	Poor Sleep in Multiple Sclerosis Correlates with Beck Depression Inventory Values, but Not with Polysomnographic Data. Sleep Disorders, 2016, 2016, 1-5.	1.5	17
310	Longitudinal Intravital Imaging of the Retina Reveals Long-term Dynamics of Immune Infiltration and Its Effects on the Glial Network in Experimental Autoimmune Uveoretinitis, without Evident Signs of Neuronal Dysfunction in the Ganglion Cell Layer. Frontiers in Immunology, 2016, 7, 642.	4.9	20
311	Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study. PLoS ONE, 2016, 11, e0147968.	2.5	10
312	RETINAL LESION EVOLUTION IN SUSAC SYNDROME. Retina, 2016, 36, 366-374.	1.9	25
313	Ranking of Dystonia Severity by Pairwise Video Comparison. Movement Disorders Clinical Practice, 2016, 3, 587-595.	1.7	0
314	Widespread inflammation in CLIPPERS syndrome indicated by autopsy and ultra-high-field 7T MRI. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e226.	6.8	47
315	The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. EPMA Journal, 2016, 7, 25.	6.1	61
316	A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms. Cell Reports, 2016, 15, 2136-2146.	6.3	392
317	The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology, 2016, 86, 2303-2309.	1.1	345
318	Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: A peptide microarray-based case-control study. Journal of Neuroimmunology, 2016, 297, 56-62.	2.4	11
319	Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0-Tesla MRI clinical study. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 535-541.	2.0	10
320	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German "Austrian retrospective multicenter study in patients with a clinically isolated syndrome. Journal of Neurology, 2016, 263, 2499-2504.	3.8	47
321	Retinal imaging and axonal degeneration in later onset multiple sclerosis. Journal of the Neurological Sciences, 2016, 370, 1-6.	0.6	2
322	Altered paired associative stimulation-induced plasticity in NMDAR encephalitis. Annals of Clinical and Translational Neurology, 2016, 3, 101-113.	3.7	13
323	Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis. European Journal of Neurology, 2016, 23, 62-67.	3.6	55
324	Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain, 2016, 139, 2641-2652.	8.0	236

#	ARTICLE	IF	CITATIONS
325	What is the future of proof of concept studies in multiple sclerosis?. <i>Lancet Neurology</i> , The, 2016, 15, 1107-1109.	10.4	0
326	Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1131-1139.	2.8	17
327	MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e259.	6.8	42
328	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 280.	7.4	723
329	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. <i>Journal of Neuroinflammation</i> , 2016, 13, 282.	7.4	222
330	Diagnostic criteria for Susac syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1287-1295.	6.0	196
331	Stress-induced brain activity, brain atrophy, and clinical disability in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13444-13449.	7.6	30
332	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	10.9	141
333	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 281.	7.4	209
334	Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e286.	6.8	89
335	Effects of CNT Addition on Interlaminar Fracture Toughness of Carbon Fiber-Reinforced Plastic Composites. <i>Journal of the Japan Society for Composite Materials</i> , 2016, 42, 193-200.	0.3	0
336	Visual dysfunction, but not retinal thinning, following anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e198.	6.8	22
337	Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI. <i>American Journal of Neuroradiology</i> , 2016, 37, 1223-1230.	2.7	65
338	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016, 134, 281-294.	4.4	37
339	Placebo-controlled study in neuromyelitis optica – Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	3.3	66
340	Accuracy and repeatability of two methods of gait analysis – GaitRite, and Mobility Lab, in subjects with cerebellar ataxia. <i>Gait and Posture</i> , 2016, 48, 194-201.	1.6	62
341	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>Journal of Neural Transmission</i> , 2016, 123, 439-445.	2.9	32
342	Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e229.	6.8	49

#	ARTICLE	IF	CITATIONS
343	Addressing Future Challenges for Cancer Services: Part II. <i>Future Oncology</i> , 2016, 12, 445-449.	2.4	0
344	Higher-resolution MR elastography reveals early mechanical signatures of neuroinflammation in patients with clinically isolated syndrome. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 51-58.	3.6	55
345	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	5.8	337
346	Genetic lineage tracing discloses arteriogenesis as the main mechanism for collateral growth in the mouse heart. <i>Cardiovascular Research</i> , 2016, 109, 419-430.	3.7	42
347	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 574-584.	10.4	278
348	Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1476-1484.	3.3	34
349	Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. <i>Journal of Neurology</i> , 2016, 263, 575-582.	3.8	55
350	Hyperhomocysteinemia is associated with decreased apolipoprotein AI levels in normal healthy people. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 10.	1.7	4
351	Validity of visual perceptive computing for static posturography in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1596-1606.	3.3	40
352	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e204.	6.8	53
353	Autoantibodies to tetraspanins (CD9, CD81 and CD82) in demyelinating diseases. <i>Journal of Neuroimmunology</i> , 2016, 291, 78-81.	2.4	3
354	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016, 263, 140-149.	3.8	60
355	Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2016, 22, 160-173.	3.3	62
356	Structural Hippocampal Damage Following Anti-N-Methyl-D-Aspartate Receptor Encephalitis. <i>Biological Psychiatry</i> , 2016, 79, 727-734.	1.3	127
357	Afferent Visual Pathway Affection in Patients with PMP22 Deletion-Related Hereditary Neuropathy with Liability to Pressure Palsies. <i>PLoS ONE</i> , 2016, 11, e0164617.	2.5	6
358	Accuracy and Reliability of the Kinect Version 2 for Clinical Measurement of Motor Function. <i>PLoS ONE</i> , 2016, 11, e0166532.	2.5	197
359	An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups. <i>Oncotarget</i> , 2016, 7, 8743-8755.	2.1	37
360	Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 879-886.	1.5	15

#	ARTICLE	IF	CITATIONS
361	Progressive Multiple Sclerosis (SP and PP MS). , 2016, , 135-150.		0
362	Effects of diazoxide in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e147.	6.8	9
363	Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 196.	7.4	28
364	Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study. <i>BMC Neurology</i> , 2015, 15, 265.	1.8	8
365	Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management. <i>EPMA Journal</i> , 2015, 6, 16.	6.1	36
366	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015, 39, 601-608.	1.3	15
367	Periodic limb movements during REM sleep in multiple sclerosis: a previously undescribed entity. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 2323.	2.2	13
368	Comparison of Standard Versus Wide-Field Composite Images of the Corneal Subbasal Layer by In Vivo Confocal Microscopy. , 2015, 56, 5801.		39
369	Sleep Disorders Reduce Health-Related Quality of Life in Multiple Sclerosis (Nottingham Health) Tj ETQq1 1 0.784314 rgBT /Overlock 10 16, 16514-16528.	4.2	43
370	Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration. <i>PLoS ONE</i> , 2015, 10, e0128386.	2.5	17
371	Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1. <i>PLoS ONE</i> , 2015, 10, e0130251.	2.5	19
372	Optical coherence tomography in neurodegenerative and other neurologic diseases. , 2015, , 128-144.		0
373	No Evidence for Retinal Damage Evolving from Reduced Retinal Blood Flow in Carotid Artery Disease. <i>BioMed Research International</i> , 2015, 2015, 1-8.	2.0	26
374	Reliability of Intra-Retinal Layer Thickness Estimates. <i>PLoS ONE</i> , 2015, 10, e0137316.	2.5	76
375	Studying Axonal Outgrowth and Regeneration of the Corticospinal Tract in Organotypic Slice Cultures. <i>Journal of Neurotrauma</i> , 2015, 32, 1465-1477.	3.6	14
376	<i>Toxoplasma gondii</i> seropositivity is negatively associated with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 285, 119-124.	2.4	27
377	Oxasqualenoids from <i>Laurencia viridis</i> : Combined Spectroscopicâ€“Computational Analysis and Antifouling Potential. <i>Journal of Natural Products</i> , 2015, 78, 712-721.	3.0	34
378	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	9.3	59

#	ARTICLE	IF	CITATIONS
379	Does Nrf2 help nerves to survive?. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e105.	6.8	0
380	Height estimation from speech signals using i-vectors and least-squares support vector regression. , 2015, , .		7
381	7T MRI in natalizumab-associated PML and ongoing MS disease activity. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e171.	6.8	20
382	Genetic Creutzfeldt-Jakob disease mimicking chronic inflammatory demyelinating polyneuropathy. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e173.	6.8	5
383	Tracking CNS and systemic sources of oxidative stress during the course of chronic neuroinflammation. <i>Acta Neuropathologica</i> , 2015, 130, 799-814.	7.9	83
384	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015, 21, 678-688.	3.3	213
385	Optic radiation damage in multiple sclerosis is associated with visual dysfunction and retinal thinning – an ultrahigh-field MR pilot study. <i>European Radiology</i> , 2015, 25, 122-131.	4.6	85
386	Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 487-495.	4.6	66
387	Effects of Cold Rolling and Strain-Induced Martensite Formation in a SAF 2205 Duplex Stainless Steel. <i>Metallurgical and Materials Transactions A: Physical Metallurgy and Materials Science</i> , 2015, 46, 577-586.	2.2	64
388	Pushing the boundaries of neuromyelitis optica. <i>Neurology</i> , 2015, 85, 118-119.	1.1	14
389	Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. <i>Journal of Neurology</i> , 2015, 262, 1379-1384.	3.8	49
390	The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. <i>Current Treatment Options in Neurology</i> , 2015, 17, 354.	1.9	52
391	MRI characteristics of neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2015, 84, 1165-1173.	1.1	549
392	Iridodonesis as a cause of recurrent vertigo. <i>Neurology</i> , 2015, 85, 1353-1353.	1.1	0
393	Trophic network architecture of root-associated bacterial communities determines pathogen invasion and plant health. <i>Nature Communications</i> , 2015, 6, 8413.	13.2	415
394	Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency. <i>Journal of Neurology</i> , 2015, 262, 1927-1935.	3.8	14
395	Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. <i>Neurology</i> , 2015, 85, 521-527.	1.1	24
396	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. <i>Neurology</i> , 2015, 85, 610-618.	1.1	53

#	ARTICLE	IF	CITATIONS
397	Temporal retinal nerve fibre layer thinning in cluster headache patients detected by optical coherence tomography. <i>Cephalgia</i> , 2015, 35, 946-958.	4.2	13
398	Aktuelle Immuntherapie der Multiplen Sklerose. <i>Der Nervenarzt</i> , 2015, 86, 1031-1044.	0.8	6
399	Association of serum Epstein-Barr nuclear antigen-1 antibodies and intrathecal immunoglobulin synthesis in early multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 285, 156-160.	2.4	21
400	Signaling networks in MS: A systems-based approach to developing new pharmacological therapies. <i>Multiple Sclerosis Journal</i> , 2015, 21, 138-146.	3.3	24
401	Vessel Labeling in Combined Confocal Scanning Laser Ophthalmoscopy and Optical Coherence Tomography Images: Criteria for Blood Vessel Discrimination. <i>PLoS ONE</i> , 2014, 9, e102034.	2.5	14
402	Multimodal Retinal Vessel Analysis in CADASIL Patients. <i>PLoS ONE</i> , 2014, 9, e112311.	2.5	28
403	Optical coherence tomography for retinal imaging in multiple sclerosis. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2014, 4, 153.	1.4	19
404	Retinal Segmentation to Demonstrate Hyperplasia in Ataxia of Charlevoix-Saguenay: Critique on Study Methodology and Results. , 2014, 55, 4728.		1
405	Chandrayaan-1 observations of backscattered solar wind protons from the lunar regolith: Dependence on the solar wind speed. <i>Journal of Geophysical Research E: Planets</i> , 2014, 119, 968-975.	3.6	28
406	Detailing intra-lesional venous lumen shrinking in multiple sclerosis investigated by sFLAIR MRI at 7-T. <i>Journal of Neurology</i> , 2014, 261, 2032-2036.	3.8	17
407	Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 49.	11.8	23
408	Flashback and Turbulent Flame Speed Measurements in Hydrogen/Methane Flames Stabilized by a Low-Swirl Injector at Elevated Pressures and Temperatures. <i>Journal of Engineering for Gas Turbines and Power</i> , 2014, 136, .	1.2	23
409	Dynamic formation of macular microcysts independent of vitreous traction changes. <i>Neurology</i> , 2014, 83, 73-77.	1.1	47
410	Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. <i>Journal of Neuroinflammation</i> , 2014, 11, 129.	7.4	25
411	Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 411-418.	6.0	66
412	The activity of catechol-O-methyltransferase (COMT) is not impaired by high doses of epigallocatechin-3-gallate (EGCG) in vivo. <i>European Journal of Pharmacology</i> , 2014, 740, 645-651.	3.6	46
413	Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. <i>Journal of Neuroinflammation</i> , 2014, 11, 46.	7.4	103
414	Metabolic Evidence for Cerebral Neurodegeneration in Spinocerebellar Ataxia Type 1. <i>Cerebellum</i> , 2014, 13, 199-206.	2.7	14

#	ARTICLE	IF	CITATIONS
415	Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. BMC Neurology, 2014, 14, 31.	1.8	46
416	Ultrahochfeld-MRT im Kontext neurologischer Erkrankungen. Der Nervenarzt, 2014, 85, 445-458.	0.8	7
417	Retinal nerve fibre layer thickness correlates with brain white matter damage in multiple sclerosis: A combined optical coherence tomography and diffusion tensor imaging study. Multiple Sclerosis Journal, 2014, 20, 1904-1907.	3.3	37
418	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of Neurology, 2014, 261, 1-16.	3.8	502
419	Chronic cerebrospinal venous insufficiency in multiple sclerosis: the final curtain. Lancet, The, 2014, 383, 106-108.	12.1	14
420	Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Multiple Sclerosis Journal, 2014, 20, 295-303.	3.3	118
421	Complement regulatory proteins (CD46, 55 and 59) expressed on Schwann cells: Immune targets in demyelinating neuropathies?. Journal of Neuroimmunology, 2014, 276, 172-174.	2.4	8
422	Identical lesion morphology in primary progressive and relapsingâ€“remitting MS â€“an ultrahigh field MRI study. Multiple Sclerosis Journal, 2014, 20, 1866-1871.	3.3	40
423	Converse flexoelectric effect in the SrTiO3 single crystal. Physics of the Solid State, 2014, 56, 1352-1354.	0.5	25
424	Reply to: Photoreceptor layer thinning in Parkinsonian syndromes. Movement Disorders, 2014, 29, 1223-1224.	4.3	2
425	Oxidative damage to mitochondria at the nodes of Ranvier precedes axon degeneration in ex vivo transected axons. Experimental Neurology, 2014, 261, 127-135.	4.1	38
426	The investigation of acute optic neuritis: a review and proposed protocol. Nature Reviews Neurology, 2014, 10, 447-458.	10.0	255
427	Increased Catabolic State in Spinocerebellar Ataxia Type 1 Patients. Cerebellum, 2014, 13, 440-446.	2.7	17
428	Using perceptive computing in multiple sclerosis - the Short Maximum Speed Walk test. Journal of NeuroEngineering and Rehabilitation, 2014, 11, 89.	4.8	48
429	Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clinical and Experimental Immunology, 2014, 176, 149-164.	2.7	286
430	Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Multiple Sclerosis Journal, 2014, 20, 617-620.	3.3	49
431	Multiple sclerosis: The elevated antibody response to Epsteinâ€“Barr virus primarily targets, but is not confined to, the glycineâ€“alanine repeat of Epsteinâ€“Barr nuclear antigen-1. Journal of Neuroimmunology, 2014, 272, 56-61.	2.4	35
432	Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Medicine, 2014, 15, 5-14.	2.3	103

#	ARTICLE	IF	CITATIONS
433	Photoreceptor layer thinning in idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1163-1170.	4.3	85
434	Optimal management of multiple sclerosis during pregnancy: current perspectives. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2014, 4, 111.	1.4	4
435	High prevalence of <scp>NMDA</scp> receptor IgA/IgM antibodies in different dementia types. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 822-832.	3.7	115
436	Pregnancy in Multiple Sclerosis: A Questionnaire Study. <i>PLoS ONE</i> , 2014, 9, e99106.	2.5	9
437	Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 112.	1.7	46
438	Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?. <i>EPMA Journal</i> , 2013, 4, 5.	6.1	81
439	Can we prevent or treat multiple sclerosis by individualised vitamin D supply?. <i>EPMA Journal</i> , 2013, 4, 4.	6.1	44
440	Treatment of sleep disorders may improve fatigue in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1826-1830.	1.4	64
441	Predicting discharge coefficient of compound broad-crested weir by using genetic programming (GP) and artificial neural network (ANN) techniques. <i>Arabian Journal of Geosciences</i> , 2013, 6, 2709-2717.	1.4	41
442	Biometric interaction. , 2013, , .		2
443	Progressive multiple sclerosis: desperately seeking remedy. <i>Lancet Neurology</i> , The, 2013, 12, 840-841.	10.4	2
444	Cerebral magnetic resonance elastography in supranuclear palsy and idiopathic Parkinson's disease. <i>NeuroImage: Clinical</i> , 2013, 3, 381-387.	2.8	78
445	A blood based 12-miRNA signature of Alzheimer disease patients. <i>Genome Biology</i> , 2013, 14, R78.	9.2	454
446	Tumefactive multiple sclerosis and fingolimod. <i>Neurology</i> , 2013, 81, 1648-1649.	1.1	8
447	Cladribine in multiple sclerosis: pitfalls in a new treatment landscape. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1-3.	1.9	1
448	Periventricular venous density in multiple sclerosis is inversely associated with T2 lesion count: a 7 Tesla MRI study. <i>Multiple Sclerosis Journal</i> , 2013, 19, 316-325.	3.3	54
449	Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation. <i>Journal of Neuroimmunology</i> , 2013, 254, 165-169.	2.4	30
450	The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. <i>Journal of Neuroimmunology</i> , 2013, 262, 66-71.	2.4	31

#	ARTICLE	IF	CITATIONS
451	Characteristics of Susac syndrome: a review of all reported cases. <i>Nature Reviews Neurology</i> , 2013, 9, 307-316.	10.0	308
452	Functional and structural brain changes in anti- α -methylglutamate receptor encephalitis. <i>Annals of Neurology</i> , 2013, 74, 284-296.	5.8	174
453	Hope for a rare disease: eculizumab in neuromyelitis optica. <i>Lancet Neurology</i> , The, 2013, 12, 529-531.	10.4	13
454	Low contrast visual acuity testing is associated with cognitive performance in multiple sclerosis: a cross-sectional pilot study. <i>BMC Neurology</i> , 2013, 13, 167.	1.8	38
455	T-cell homeostasis in pediatric multiple sclerosis. <i>Neurology</i> , 2013, 81, 784-792.	1.1	66
456	Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. <i>Multiple Sclerosis Journal</i> , 2013, 19, 443-450.	3.3	102
457	Bilateral vertebral artery dissection, agenesis of both ICAs, and connective tissue aberrations. <i>Neurology</i> , 2013, 80, 1442-1443.	1.1	4
458	Higher macular volume in patients with MS receiving fingolimod. <i>Neurology</i> , 2013, 80, 128-129.	1.1	21
459	Are there Epstein-Barr virus seronegative patients with multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1242-1243.	3.3	13
460	Nephronophthisis Cannot Be Detected by Urinary Screening Program. <i>Clinical Pediatrics</i> , 2013, 52, 759-761.	0.9	5
461	Breastfeeding is associated with lower risk for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 553-558.	3.3	53
462	Olfactory Dysfunction in Patients with Neuromyelitis Optica. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-4.	0.8	20
463	Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2013, 20, 1170-1176.	3.6	46
464	What Went Wrong? the Flawed Concept of Cerebrospinal Venous Insufficiency. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 657-668.	4.6	51
465	Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1887-1895.	3.3	143
466	Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon- γ Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2013, 8, e70626.	2.5	44
467	Optic Neuritis Is Associated with Inner Nuclear Layer Thickening and Microcystic Macular Edema Independently of Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e71145.	2.5	105
468	Enlargement of Cerebral Ventricles as an Early Indicator of Encephalomyelitis. <i>PLoS ONE</i> , 2013, 8, e72841.	2.5	22

#	ARTICLE	IF	CITATIONS
469	Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e66151.	2.5	166
470	In vitro adherence of periodontopathic bacteria to zirconia and titanium surfaces. <i>Dental Materials Journal</i> , 2013, 32, 101-106.	1.8	44
471	Concomitant amyotrophic lateral sclerosis and paraclinical laboratory features of multiple sclerosis: coincidence or causal relationship?. <i>BMJ Case Reports</i> , 2013, 2013, bcr2012007975.	0.5	4
472	Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. <i>British Journal of Ophthalmology</i> , 2012, 96, 62-67.	4.0	69
473	Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. <i>Neurology</i> , 2012, 79, 708-714.	1.1	196
474	Multiple Sclerosis Lesions and Irreversible Brain Tissue Damage. <i>Archives of Neurology</i> , 2012, 69, 739-45.	4.5	70
475	Fatigue in multiple sclerosis: which patient should be referred to a sleep specialist?. <i>Multiple Sclerosis Journal</i> , 2012, 18, 248-249.	3.3	35
476	Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2012, 69, 239.	4.5	279
477	Is It Too Early to Predict the Failure of Natalizumab in NMO?â€”Reply. <i>Archives of Neurology</i> , 2012, 69, 1085.	4.5	5
478	Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-10.	0.8	113
479	<i>N,N</i> -(1,4-Phenylene)bis(2-bromo-2-methylpropanamide). <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2012, 68, o811-o811.	0.2	1
480	Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 75-79.	3.8	39
481	Can we overcome the â€œclinico-radiological paradoxâ€™ in multiple sclerosis?. <i>Journal of Neurology</i> , 2012, 259, 2151-2160.	3.8	45
482	Dynamics of saccade parameters in multiple sclerosis patients with fatigue. <i>Journal of Neurology</i> , 2012, 259, 2656-2663.	3.8	50
483	Fatigue and sleep disorders in multiple sclerosis: is obstructive sleep apnea a link?. <i>Sleep and Breathing</i> , 2012, 16, 949-950.	1.9	0
484	Exercise in multiple sclerosis – an integral component of disease management. <i>EPMA Journal</i> , 2012, 3, 2.	6.1	64
485	Magnetic resonance elastography reveals altered brain viscoelasticity in experimental autoimmune encephalomyelitis. <i>NeuroImage: Clinical</i> , 2012, 1, 81-90.	2.8	103
486	Fatigue in multiple sclerosis: a diagnostic and therapeutic challenge. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 791-793.	1.9	11

#	ARTICLE	IF	CITATIONS
487	Efficacy of vision restoration therapy after optic neuritis (VISION study): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 94.	1.7	8
488	Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. <i>EPMA Journal</i> , 2012, 3, 9.	6.1	59
489	Multi-scale classification of disease using structural MRI and wavelet transform. <i>NeuroImage</i> , 2012, 62, 48-58.	4.4	63
490	Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1592-1599.	3.3	136
491	Brain Viscoelasticity Alteration in Chronic-Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e29888.	2.5	208
492	Is Metabolic Flexibility Altered in Multiple Sclerosis Patients?. <i>PLoS ONE</i> , 2012, 7, e43675.	2.5	52
493	Optic Nerve Head Quantification in Idiopathic Intracranial Hypertension by Spectral Domain OCT. <i>PLoS ONE</i> , 2012, 7, e36965.	2.5	70
494	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. <i>Journal of Neuroinflammation</i> , 2012, 9, 14.	7.4	614
495	Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. <i>International Journal of Pharmaceutics</i> , 2012, 423, 509-515.	5.4	161
496	Organ transplantation from a donor colonized with a multidrug-resistant organism: a case report. <i>Transplant Infectious Disease</i> , 2012, 14, 296-299.	1.6	57
497	Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 15.	1.7	80
498	3D Optic Nerve Head Segmentation in Idiopathic Intracranial Hypertension. <i>Informatik Aktuell</i> , 2012, , 262-267.	0.0	4
499	Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS. <i>PLoS ONE</i> , 2012, 7, e38741.	2.5	53
500	Mitoxantrone Induces Natural Killer Cell Maturation in Patients with Secondary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e39625.	2.5	21
501	The German Healthcare System. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2012, , 45-67.	0.0	1
502	Safe Laparoscopic Entry Technique – A Follow-Up Retrospective Review of the Last 2000 Cases. <i>Journal of Minimally Invasive Gynecology</i> , 2011, 18, S131.	0.6	0
503	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1067-1073.	3.3	145
504	Imaging the Visual Pathway in Neuromyelitis Optica. <i>Multiple Sclerosis International</i> , 2011, 2011, 1-5.	0.8	22

#	ARTICLE	IF	CITATIONS
505	Metabolic Changes in the Visual Cortex Are Linked to Retinal Nerve Fiber Layer Thinning in Multiple Sclerosis. PLoS ONE, 2011, 6, e18019.	2.5	76
506	MRI Pattern Recognition in Multiple Sclerosis Normal-Appearing Brain Areas. PLoS ONE, 2011, 6, e21138.	2.5	48
507	Perfluorocarbon Particle Size Influences Magnetic Resonance Signal and Immunological Properties of Dendritic Cells. PLoS ONE, 2011, 6, e21981.	2.5	46
508	Temporal Retinal Nerve Fiber Loss in Patients with Spinocerebellar Ataxia Type 1. PLoS ONE, 2011, 6, e23024.	2.5	58
509	The Influence of Physiological Aging and Atrophy on Brain Viscoelastic Properties in Humans. PLoS ONE, 2011, 6, e23451.	2.5	153
510	The Surgeon and the Law on Patient's Rights for Minors. Acta Chirurgica Belgica, 2011, 111, 119-124.	0.7	5
511	Environmental factors in early childhood are associated with multiple sclerosis: a case-control study. BMC Neurology, 2011, 11, 123.	1.8	30
512	The German healthcare system. EPMA Journal, 2010, 1, 535-547.	6.1	24
513	No cerebrocervical venous congestion in patients with multiple sclerosis. Annals of Neurology, 2010, 68, 173-183.	5.8	244
514	No Evidence for XMRV in German CFS and MS Patients with Fatigue Despite the Ability of the Virus to Infect Human Blood Cells In Vitro. PLoS ONE, 2010, 5, e15632.	2.5	50
515	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the Neurological Sciences, 2010, 298, 158-162.	0.6	171
516	Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. Journal of Neuroinflammation, 2010, 7, 52.	7.4	184
517	Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. Neurochemistry International, 2010, 57, 662-667.	3.9	15
518	Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clinical Neurology and Neurosurgery, 2010, 112, 647-652.	1.4	109
519	MR-elastography reveals degradation of tissue integrity in multiple sclerosis. NeuroImage, 2010, 49, 2520-2525.	4.4	271
520	Encephalopathy, visual disturbance and hearing loss—recognizing the symptoms of Susac syndrome. Nature Reviews Neurology, 2009, 5, 683-688.	10.0	59
521	SEVERE CARDIAC FAILURE IN A PATIENT WITH MULTIPLE SCLEROSIS FOLLOWING LOW-DOSE MITOXANTRONE TREATMENT. Neurology, 2009, 73, 991-993.	1.1	38
522	Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Annals of Neurology, 2009, 66, 310-322.	5.8	152

#	ARTICLE	IF	CITATIONS
523	A woman with acute myelopathy in pregnancy: case presentation. <i>BMJ: British Medical Journal</i> , 2009, 339, b3862-b3862.	5.6	6
524	A woman with acute myelopathy in pregnancy: case progression. <i>BMJ: British Medical Journal</i> , 2009, 339, b4025-b4025.	5.6	2
525	A woman with acute myelopathy in pregnancy: case outcome. <i>BMJ: British Medical Journal</i> , 2009, 339, b4026-b4026.	5.6	31
526	Treatment-resistant chronic headaches and focal pachymeningitis in a 46-year-old man: a rare presentation of Wegener's granulomatosis. <i>Lancet Neurology</i> , The, 2008, 7, 368-372.	10.4	12
527	Multiple sclerosis following etanercept treatment for ankylosing spondylitis. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 397-399.	1.2	34
528	Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 202-214.	1.4	296
529	Perivascular spaces—MRI marker of inflammatory activity in the brain?. <i>Brain</i> , 2008, 131, 2332-2340.	8.0	209
530	Tools to share good chairside teaching practice: a clinical scenario and appreciative questionnaire. <i>British Dental Journal</i> , 2008, 205, 603-606.	1.0	5
531	Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2008, 3, e1928.	2.5	110
532	Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2007, 16, 479-484.	2.0	21
533	Evaluation of a combined thiourea and hydrogen peroxide regimen to bleach bloodstained teeth. <i>Australian Dental Journal</i> , 2007, 52, 33-40.	1.6	10
534	Cerebral blood perfusion changes in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2007, 259, 16-20.	0.6	53
535	Major hydrogeochemical processes in the two reservoirs of the Yangbajing geothermal field, Tibet, China. <i>Journal of Volcanology and Geothermal Research</i> , 2007, 166, 255-268.	2.1	88
536	Revised diagnostic criteria for neuromyelitis optica—incorporation of NMO-IgG status. <i>Nature Clinical Practice Neurology</i> , 2007, 3, E1-E1.	1.4	15
537	Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica. <i>PLoS Medicine</i> , 2007, 4, e133.	8.4	189
538	Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon-1a. <i>World Journal of Gastroenterology</i> , 2007, 13, 3638.	3.4	33
539	Bilateral meralgia paresthetica after cesarian section with epidural analgesia. <i>Journal of the Peripheral Nervous System</i> , 2006, 11, 98-99.	2.5	9
540	Rezidivierendes reversibles posteriores Leukenzephalopathiesyndrom unter Chemotherapie mit Cisplatin und 5-Fluorouracil. <i>Der Nervenarzt</i> , 2006, 77, 706-710.	0.8	7

#	ARTICLE	IF	CITATIONS
541	Unprecedented Association of [Mo ₆ Bri ₇ YiBra ₆] ₃ Cluster Units and [MoIII ₆ Br ₆] ₃ Complexes: Synthesis, Crystal Structures, and Properties of the Double Salts Rb ₃ [Mo ₆ Bri ₇ YiBra ₆](Rb ₃ [MoBr ₆]) ₃ (Y=Se, Te). Chemistry - A European Journal, 2006, 12, 6419-6425.	3.9	6
542	High-Speed and Large-Capacity RFID Inventory Method Using 1-Bit Flag. , 2006, , .		2
543	Magnetic and dynamic mechanical properties of barium ferrite natural rubber composites. Journal of Materials Processing Technology, 2005, 160, 229-233.	6.4	91
544	4-Allyl-2-(morpholin-4-ylmethyl)-5-(pyridin-4-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione. Acta Crystallographica Section E: Structure Reports Online, 2005, 61, o1953-o1955.	0.2	2
545	Postural hand tremor before and following liver transplantation and immunosuppression with cyclosporine or tacrolimus in patients without clinical signs of hepatic encephalopathy. Clinical Transplantation, 2004, 18, 429-433.	1.6	17
546	Levetiracetam in Focal Epilepsy and Hepatic Porphyria: A Case Report. Epilepsia, 2004, 45, 559-560.	4.6	37
547	Application of a figure-of-merit for optical remote sensors to an airborne hyperspectral sensor. , 2004, 5546, 49.		0
548	Operation of a 33-W, continuous-wave, self-adaptive, solid-state laser oscillator. Journal of the Optical Society of America B: Optical Physics, 2003, 20, 857.	2.0	13
549	The effect of negative emotional context on neural and behavioural responses to oesophageal stimulation. Brain, 2003, 126, 669-684.	8.0	178
550	Landscaping to Learnscaping. Australian Journal of Environmental Education, 1997, 13, 91-92.	2.2	0
551	Identification with liquid chromatography-ionspray mass spectrometry of the metabolites of the enantiomers N-methyl dextrorphan and N-methyl levorphanol after rat liver perfusion. Biological Mass Spectrometry, 1993, 22, 226-234.	0.5	11
552	Chitosan Coating Effect on Storability and Quality of Fresh Strawberries. Journal of Food Science, 1991, 56, 1618-1620.	3.2	379
553	Haematological Adverse Effects of Histamine H ₂ -Receptor Antagonists. Medical Toxicology, 1988, 3, 430-448.	1.4	50
554	Registration of INIA 66R Wheat. Crop Science, 1985, 25, 1129-1129.	1.9	0
555	Preparation and properties of high modulus-tensile strength polymeric materials. Polymer Engineering and Science, 1980, 20, 167-171.	3.1	8
556	The crux of course design in probability. Educational Studies in Mathematics, 1974, 5, 261-277.	3.1	9
557	Volatility During the Financial Crisis Through the Lens of High Frequency Data: A Realized GARCH Approach. SSRN Electronic Journal, 0, , .	0.3	8
558	Title is missing!. , 0, , .		0

#	ARTICLE	IF	CITATIONS
559	Cognitive-motor interference in multiple sclerosis and healthy controls: results from single, dual, and triple task posturography. <i>Exploration of Neuroprotective Therapy</i> , 0, , 273-287.	1.9	0
560	Altered brain perfusion and oxygen levels relate to sleepiness and attention in postâ€œscp>COVID</scp> syndrome. <i>Annals of Clinical and Translational Neurology</i> , 0, , .	3.7	0
561	Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis. <i>Journal of Neurology</i> , 0, , .	3.8	0
562	Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis. <i>Journal of Neurology</i> , 0, , .	3.8	0
563	Hippocampal hub failure is linked to long-term memory impairment in anti-NMDA-receptor encephalitis: insights from structural connectome graph theoretical network analysis. <i>Journal of Neurology</i> , 0, , .	3.8	0
564	Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network. <i>Annals of Clinical and Translational Neurology</i> , 0, , .	3.7	0
565	B cell and aquaporinâ€4 antibody relationships with neuromyelitis optica spectrum disorder activity. <i>Annals of Clinical and Translational Neurology</i> , 0, , .	3.7	0